Zepbound®

Both are FDA-approved for chronic weight management, but they work through different mechanisms. Wegovy (semaglutide) activates one receptor (GLP-1), while Zepbound (tirzepatide) activates two (GIP and GLP-1). In head-to-head clinical trials, tirzepatide showed greater average weight loss than semaglutide. Zepbound also has a unique FDA approval for treating moderate to severe obstructive sleep apnea in adults with obesity. Your clinician will recommend the best option based on your health history, insurance coverage, and individual response.

The most common side effects are gastrointestinal: nausea, diarrhea, constipation, and decreased appetite. Some patients also experience fatigue during the first weeks of treatment. These are typically mild to moderate and tend to improve as your body adjusts, especially with PEAK's gradual titration approach. Your clinician will monitor for any side effects and adjust your treatment plan as needed.

Coverage varies by insurance plan. Many commercial plans cover Zepbound for weight management, though some require prior authorization or have specific eligibility criteria. PEAK accepts Anthem, Cigna, Aetna, UnitedHealthcare, Sentara, and TRICARE commercial plans, and does not accept Medicare or Medicaid plans. PEAK handles the prior authorization process for you and will confirm coverage before you begin treatment. If Zepbound isn't covered, your clinician may recommend an alternative or discuss cash-pay options including the Zepbound vial program. View our full insurance and pricing information.

The standard Zepbound pen is the pre-filled auto-injector that can be covered by insurance. The Zepbound vial is the same FDA-approved tirzepatide from Eli Lilly, but in a multi-dose vial format that's available at a lower cash-pay price point. Both contain the same medication — the difference is the delivery format and how you pay for it. Your clinician can help determine which option makes the most sense for you.

Obesity is a chronic condition, and treatment duration varies by individual. Some patients continue medication long-term for sustained weight management, while others may eventually taper off — especially if they've developed strong nutritional and behavioral habits during treatment. Research does show that weight regain is common when GLP-1 medications are discontinued without ongoing support, which is why PEAK's approach emphasizes building habits alongside medication.

Yes. If you are currently on Wegovy, Saxenda, or a compounded GLP-1, your PEAK clinician can help you transition to Zepbound safely. The switch involves adjusting your dosing schedule and monitoring your response. Many patients come to PEAK specifically because they want to move from a telehealth-only prescription to a clinician-managed program with nutritional support.